Trials / Active Not Recruiting
Active Not RecruitingNCT05703269
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Hypofractionated Radiotherapy vs Single Fraction Radiosurgery for Brain Metastasis Patients on Immunotherapy (HYPOGRYPHE)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhibitor (ICI) therapy. This study will compare the usual care treatment of single fraction stereotactic radiosurgery (SSRS) given on one day versus fractionated stereotactic radiosurgery (FSRS), which is a lower dose of radiation given over a few days to determine if FSRS is better or worse at reducing side effects than usual care treatment.
Detailed description
This study is an open-label, randomized, Phase III trial designed to ascertain whether fractionated stereotactic radiosurgery (FSRS) results in lower incidence of Grade 2 or higher adverse radiation effect (ARE) by 9 months compared to single fraction stereotactic radiosurgery (SSRS) in patients with large brain metastases who have received or will receive immune checkpoint inhibitor (ICI) targeted to the PD-1/PD-L1 axis within 30 days of stereotactic radiosurgery (SRS). Participants will be randomized 1:1 to either SSRS or FSRS, using a minimization randomization strategy considering 5 prognostic factors of interest: radiosurgery platform (gamma knife vs. LINAC), timing of immunotherapy relative to radiation (ICI within 30 days prior to Day 1 of SRS or not), surgical status (any resection cavity vs intact metastases only), predominant tumor type (Melanoma vs. all others), and prior courses of SRS for brain metastases (yes vs. no).
Conditions
- NSCLC
- Renal Cell Carcinoma
- Breast Carcinoma
- Melanoma
- Brain Metastases, Adult
- Non-small Cell Lung Cancer
- SCLC
- Small-cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | single fraction stereotactic radiosurgery (SSRS) | SSRS is an advanced radiation technique that delivers high dose precision radiation in a single dose to discrete intracranial lesions. |
| RADIATION | fractionated stereotactic radiosurgery (FSRS) | FSRS is an advanced radiation technique that uses a lower dose precision radiation delivered over 3 to 5 treatments given daily or every other day to intracranial lesions. |
Timeline
- Start date
- 2023-07-11
- Primary completion
- 2028-03-31
- Completion
- 2028-03-31
- First posted
- 2023-01-30
- Last updated
- 2026-04-06
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05703269. Inclusion in this directory is not an endorsement.